CAMBRIDGE, Mass., March 21 /PRNewswire-FirstCall/ -- Biopure Corporation announced today that it has received notification from The Nasdaq Stock Market that the company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq National Market, pursuant to Marketplace Rule 4450(a)(5).
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body’s tissues. Hemopure(R) [hemoglobin glutamer -- 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The product has not been approved for sale in other countries. Biopure plans to apply in Europe, in mid 2006, for approval of an acute anemia indication in orthopedic surgery patients. The company is developing Hemopure for a potential indication in cardiovascular ischemia, in addition to supporting the U.S. Naval Medical Research Center’s government-funded development of a potential out-of-hospital trauma indication. The company’s veterinary product Oxyglobin(R) [hemoglobin glutamer -- 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs.
Contact: Douglas Sayles Biopure Corporation (617) 234-6826 IR@biopure.com
Biopure Corporation
CONTACT: Douglas Sayles of Biopure Corporation, +1-617-234-6826,IR@biopure.com
Web site: http://www.biopure.com/
Company News On-Call: http://www.prnewswire.com/comp/131224.html /
